Bugs & Drugs

I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens and pipeline reviews. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • CDC 2019: Newsletter is here, report itself is here.
  • WHO 2017: Newsletter is here, report itself is here.
  • CDC 2013: Report itself is here.
  • ESKAPE list 2008-9: The original papers are here:
    • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
    • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
  • Comparative summary of all 4 priority pathogen lists as a PowerPoint deck is here.
    • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class. 

Pipeline Reviews

  • Reviews by WHO
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of April 2020)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2019.
    • Non-traditional products are separately summarized here.
  • Independent reviews

New YouTube videos! Cost of R&D, Antibiotic value, and Lessons from COVID

Dear All, For those of you who enjoy listening to learn, here are some updates to recent newsletters that you might enjoy: 9 Jan 2021 (newsletter): “All-In Cost of a New Antibiotic From Discovery to 10 Years on Market“ As you’ll recall, the key point is that the all-in cost is ~$1.7b per new molecule after

JPIAMR call: 25m Euro for interventions to reduce/prevent AMR

Dear All, JPIAMR is today launching an international call entitled “One Health interventions to prevent or reduce the development and transmission of AMR.” The call, with financial support from the European Commission, includes 30 funding organisations from 21 JPIAMR member countries and has a total estimated call budget of 24.9 million Euro. Here’s the description of

Scroll to Top